You are here:  Home     June 28, 2016


National Pediatric Sleep Groups   
News and activities from Pediatric Sleep Groups all over the world

Pediatric Sleep


IPSA suggestions   
help us to make IPSA more complete and useful, send information about pediatric sleep activities in Your country.

After the mail ballot we have the results of the new board that is composed by:
President Christian Guilleminault (USA)
Past President Oliviero Bruni (Italy)
Vice President Patricia Franco (France)
Secretary Rosemary Horne (Australia)
Director Rosana Alves (Brazil)
Director Sarah Biggs (Australia)
Director Ron Chervin (USA)
Director Paul Gringras (UK)
Director Daniel Ng (Hong Kong)
Director Judith Owens (USA)
Director Teresa Paiva (Portugal)  


IPSA Congress 2016 - Taiwan March 11-13, 2016
Dear Friends, On behalf of the organizing committee, we are extremely happy to invite you to participate in the
IV International Pediatric Sleep Association Congress (IPSA 2016) which will be held on March 11-13, 2016, in Taipei International Convention Center, located in the heart of Taipei, Taiwan.

We sincerely hope the beauty of our city and the theme of our conference will attract you all. The IPSA 2016 serves as a premier event on the international calendar of pediatric sleep bringing together physicians, educators, basic scientists, sleep technician and clinical investigators from hospitals, industry, and academia to present and share the latest cutting-edge research results and innovative solutions in the related fields. We believe you will have a fruitful and enjoyable time during your stay in Taipei based on our solid program and the hospitality of Taipei, Taiwan aka “Formosa”.(“beautiful in Portuguese”) island, as used by the Portuguese mariners centuries ago to describe Taiwan Look forward to seeing you in Taipei, Taiwan in 2016! Best Regards, Dr. Yu-Shu Huang, Chair of IPSA 2016 and Local Organizer Dr. Daniel KK Ng, Co-Chair of IPSA 2016 Dr. Oliviero Bruni, President of IPSA Dr. Chia-Mo Lin, President of Taiwan Society of Sleep Medicine   read more...

IPSA Congress 2014 - Porto Alegre - Brazil - Sunday, September 29, 2013

It is my pleasure to present the
III Congress of the International Pediatric Sleep Association (IPSA) - Porto Alegre (Brazil) 3-5 December 2014.

The importance of sleep for health, learning and psychomotor development in infancy, childhood and adolescence has been emphasized in the pediatric research in the last two decades and it has become more and more evident that ensuring a good sleep during development is of key importance for a later healthy life.
The IPSA Congress is an influential forum for sleep practitioners from around the world to network and exchange views, whilst learning from world-class researchers about the latest scientific and clinical developments in the field.
The success of the last two Congresses in Rome 2010 and Manchester 2012 has highlighted the magnitude of Pediatric Sleep Medicine in the scientific community and we hope that the 2014 Congress will provide a perfect balance between didactic and practical needs, in order to provide the technical knowhow and up-to-date knowledge that will enable participants to improve their practice.
As traditional for IPSA, the most renowned International opinion leaders in the field of Pediatric Sleep Medicine speakers will join the Congress and will highlight the recent significant advances in both basic science and clinical sleep medicine during development.
I hope that the world paediatric sleep community will gather together in the lively city of Porto Alegre to celebrate the best clinical practice and the latest advances in Pediatric Sleep Medicine.

Oliviero Bruni
President of the International Pediatric Sleep Association


IPSA Congress 5-7 december 2012 - Manchester City (UK)

IPSA Congress 5-7th December 2012 - Manchester (UK)  


IPSA 2010 - Abstract Book




Guia SAOS Infantil Espanola

New guidelines on the diagnosis and treatment of OSA in children published by the Spanish Pediatric Sleep Group. (available only in Spanish)



[PageLinks]     TIP: Press shift while clicking on the article to open in a new window.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults.
Related Articles

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults.

J Am Acad Dermatol. 2016 Mar;74(3):491-8

Authors: Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Mastey V

BACKGROUND: The adult burden of atopic dermatitis (AD) is poorly characterized.
OBJECTIVE: We sought to characterize AD burden in adults with moderate to severe disease from the patient's perspective.
METHODS: Patient-reported outcomes collected at screening in a phase 2b clinical trial of dupilumab included pruritus numeric rating scale, 5-Dimension Pruritus Scale, subjective components of SCORing AD, Patient-Oriented Eczema Measure, Hospital Anxiety and Depression Scale, Dermatology Life Quality Index, and 5-Dimension EuroQol.
RESULTS: Most of the 380 patients had been living with AD for nearly all their lives, whereas approximately 40% were given a diagnosis as adults; 40.3% had asthma and 60.5% had other allergic conditions. Despite 48.2% of patients using systemic therapies in the past year, patients reported problems with itch frequency (85% of patients), duration (41.5% reported itching ≥18 h/d), and severity (6.5 of 10 on numeric rating scale); 55% reported AD-related sleep disturbances 5 d/wk or more. Hospital Anxiety and Depression Scale scores suggesting clinically relevant anxiety or depression were reported by 21.8% of patients. Quality of life was impaired on Dermatology Life Quality Index and 5-dimension EuroQol.
LIMITATIONS: This study had limited generalizability; conclusions may not reflect those with mild AD or not participating in a clinical trial.
CONCLUSIONS: Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.

PMID: 26777100 [PubMed - indexed for MEDLINE]

Antenatal substance misuse and smoking and newborn hypoxic challenge response.
Related Articles

Antenatal substance misuse and smoking and newborn hypoxic challenge response.

Arch Dis Child Fetal Neonatal Ed. 2016 Mar;101(2):F143-8

Authors: Ali K, Rossor T, Bhat R, Wolff K, Hannam S, Rafferty GF, Peacock JL, Greenough A

OBJECTIVES: Infants of smoking (S) and substance misusing (SM) mothers have an increased risk of sudden infant death syndrome. The aim of this study was to test the hypothesis that infants of SM or S mothers compared with infants of non-SM, non-smoking mothers (controls) would have a poorer ventilatory response to hypoxia, which was particularly marked in the SM infants.
DESIGN: Physiological study.
SETTING: Tertiary perinatal centre.
PATIENTS: 21 SM; 21 S and 19 control infants. Infants were assessed before maternity/neonatal unit discharge.
INTERVENTIONS: Maternal and infant urine samples were tested for cotinine, cannabinoids, opiates, amphetamines, methadone, cocaine and benzodiazepines.
MAIN OUTCOME MEASURES: During quiet sleep, the infants were switched from breathing room air to 15% oxygen and changes in minute volume were assessed.
RESULTS: The SM infants had a greater mean increase (p=0.028, p=0.034, respectively) and a greater magnitude of decline (p<0.001, p=0.018, respectively) in minute volume than the S infants and the controls. The rate of decline in minute volume was greater in the SM infants (p=0.008) and the S infants (p=0.011) compared with the controls.
CONCLUSIONS: Antenatal substance misuse and smoking affect the infant's ventilatory response to a hypoxic challenge.

PMID: 26290480 [PubMed - indexed for MEDLINE]


Join IPSA. It's free!!!   
Just add Your data to the membership module  

Upcoming Meetings   


Home|IPSA Mission|Board|Bylaws|Contact IPSA|Membership|Site Map
Copyright (c) 2016 IPSA Terms Of Use Privacy Statement